Humacyte, Inc.
NASDAQ:HUMABiotechnology
-$0.03 today
- Market cap
- $138.90M
- Beta
- 2.46
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$0.49
Volume 3.91M
Average 8.14M
HUMA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Humacyte, Inc.NASDAQ: HUMA
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $7.93M fell 2.5% year over year, ahead of the -10.2% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 36.1% from the prior quarter. Over 3 fiscal years it compounded at +10.9% a year.
Context
- Selling, general & admin amounted to 1529.5% of revenue in FY2025.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $39.18M (+25.7%) for the fiscal year ending Dec 2026, a step up from the +20.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $7.93M+36.1% QoQ
- Last fiscal yearDec 2025
- $31.17M+20.8% YoY
- LTMMar 2026
- $27.31M-10.2% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 31.17M USD
- Year-over-year change
- +20.8%
- 4-year CAGR
- +10.2%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.17M | +20.8% |
| FY2024 | 2024-12-31 | 25.8M | +26.5% |
| FY2023 | 2023-12-31 | 20.39M | -10.9% |
| FY2022 | 2022-12-31 | 22.88M | +8.3% |
| FY2021 | 2021-12-31 | 21.13M | — |
Selling, General & Admin vs competitors
How HUMA compares with its peers on the latest reported figures
- HUMA's LTM Mar 2026 selling, general & admin of $27.31M is the 8th highest of the 11 companies compared; the peer median is $34.68M.
- Its year-over-year change of -10.2% is the 9th highest of 11, against a peer median of +3.3%.
- Selling, general & admin amounts to 1354.8% of revenue for HUMA, versus a peer median of 99.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.7B | +29505.3% | +3.5% | — | |
| LTM Mar 2026 | $256.23M | +54.0% | +20.4% | 117.7% | |
| LTM Mar 2026 | $43.57M | -11.6% | +0.0% | 96.1% | |
| LTM Mar 2026 | $40.9M | +4.0% | +10.2% | 712.8% | |
| LTM Mar 2026 | $36.17M | -2.1% | +6.6% | 99.1% | |
| LTM Mar 2026 | $33.2M | +76.0% | +43.8% | — | |
| LTM Mar 2026 | $30.28M | -34.0% | -12.3% | — | |
| LTM Mar 2026 | $27.31M | -10.2% | +10.9% | 1354.8% | |
| LTM Mar 2026 | $26.89M | -3.6% | -3.6% | 95.3% | |
| LTM Mar 2026 | $23.69M | +2.7% | +2.7% | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $18.03M | +5.9% | +42.7% | — |
| Peer median (excluding HUMA) | $34.68M | +3.3% | +5.1% | 99.1% | |
Competitors are the stored peer set for HUMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.26M | 1.57M | 0 | 0 | 2.04M |
| Cost of Revenue | 61.34M | 8.26M | 76.55M | 7.19M | 17.05M |
| Gross Profit | (60.08M) | (6.69M) | (76.55M) | (7.19M) | (15.01M) |
| Gross Margin | -4756.8% | -427.5% | — | — | -736.5% |
| Research & Development | 61.34M | 63.26M | 76.55M | 88.6M | 69.3M |
| Selling, General & Admin | 21.13M | 22.88M | 20.39M | 25.8M | 31.17M |
| Operating Expenses | 21.13M | 77.89M | 23.5M | 107.21M | 92.43M |
| Depreciation & Amortization | 8.24M | 8.21M | 7.72M | 7.19M | 7.35M |
| EBITDA | (13.89M) | 2.45M | (96.46M) | (132.23M) | (22.24M) |
| EBITDA Margin | -1099.6% | 156.2% | — | — | -1091.2% |
| Operating Income | (81.21M) | (84.58M) | (100.05M) | (114.4M) | (107.44M) |
| Operating Margin | -6429.8% | -5404.3% | — | — | -5271.7% |
| Interest Income | 16K | 2.63M | 5.47M | 4.1M | 2.59M |
| Interest Expense | 4.35M | 6.2M | 6.6M | 9.28M | 11.25M |
| Other Income / Expenses | 54.73M | 72.61M | (10.73M) | (34.3M) | 66.6M |
| Income Before Tax | (26.48M) | (11.97M) | (110.78M) | (148.7M) | (40.83M) |
| Pre-Tax Margin | -2096.4% | -764.5% | — | — | -2003.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.48M) | (11.97M) | (110.78M) | (148.7M) | (40.83M) |
| Net Margin | -2096.4% | -764.5% | — | — | -2003.6% |
| EPS (Basic) | (0.66) | (0.12) | (1.07) | (1.26) | (0.26) |
| EPS (Diluted) | (0.66) | (0.12) | (1.07) | (1.26) | (0.26) |
| Weighted Avg Shares | 39.97M | 103.05M | 103.42M | 118.48M | 158.16M |
| Weighted Avg Shares (Diluted) | 39.97M | 103.05M | 103.42M | 118.48M | 158.16M |
Humacyte, Inc.
NASDAQ:HUMA
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.